NCT03292783: A Study of NOV1501 (ABL001) in Subject With Advanced Solid Tumors

NCT03292783
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with symptomatic or uncontrolled central nervous system (CNS) metastases 
https://ClinicalTrials.gov/show/NCT03292783

Comments are closed.

Up ↑